efpeglenatide vs Liraglutide (Victoza)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
efpeglenatide
Marketed by Hanmi Pharmaceutical and partners
NCT03353350 · Phase 3 · completed
AMPLITUDE-M was a randomized, double-blind, placebo-controlled Phase 3 trial of once-weekly efpeglenatide 2, 4 or 6 mg as monotherapy in 406 adults with type 2 diabetes not controlled by diet and exercise. The primary endpoint was the change in HbA1c at week 30. Each dose lowered HbA1c significantly more than placebo, by 0.5, 0.8 and 1.0 percentage points (p=0.0054, p<0.0001 and p<0.0001), so the primary endpoint was met. Source: the peer-reviewed trial report.
Next expected readout: November 2027 · NCT07379333 (registry estimate)
Reported efficacy
Change in Glycated Hemoglobin (HbA1c) (%) (Baseline to Week 30): Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care). (met)
Result source: NCT03353350
Liraglutide (Victoza)
Marketed by Novo Nordisk
NCT00318461 · Phase 3 · completed
This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.
Next expected readout: June 2027 · NCT03883412 (registry estimate)
Reported efficacy
Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00318461
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | efpeglenatide | Liraglutide (Victoza) |
|---|---|---|
| HbA1c, change | -1.6% vs -0.5%−1.1 vs placeboNCT033533505 other results
| -0.6% vs 0.4%−1.1 vs placeboNCT0154121527 other results
|
| Body weight, change (kg) | -1.8 vs -1.3−0.6 vs placeboNCT033533505 other results
| -2.3 vs 1.0−3.3 vs placeboNCT0154121522 other results
|
| HbA1c below 7% | —Trial running · NCT07379333 | 63.7% vs 36.5%+27.2 vs placeboNCT015412153 other results
|
| Fasting plasma glucose, change | 6.5 vs 8.6−2 vs placeboNCT033533502 other results
| -1.6 vs 1.0−2.6 vs placeboNCT0154121521 other results
|
| 3-point MACE (% with event) | —Trial running · NCT07379333 | 13% vs 14.9%−1.9 vs placeboNCT01179048 |
HbA1c, change
- efpeglenatide
- -1.6% vs -0.5%−1.1 vs placeboNCT03353350
5 other results
- -1.5% vs -0.5% NCT03353350
- -1.1% vs -0.5% NCT03353350
- -1.5% vs -0.5% NCT03353350
- -1.5% vs -0.5% NCT03353350
- -1.2% vs -0.5% NCT03353350
- Liraglutide (Victoza)
- -0.6% vs 0.4%−1.1 vs placeboNCT01541215
27 other results
- -0.6% vs -0.5% NCT00318461
- -1% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -1.0% vs -1.0% NCT00318461
- -0.4% vs -0.5% NCT00318461
- -0.7% vs -1.0% NCT00318461
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -0.7% vs 0.7% NCT01541215
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- 7.9% vs 8.9% NCT01505673
- 6.4% vs 6.4% NCT02765399
- -1.1% vs -0.5% NCT01907854
- -1.8% vs -1.2% NCT01973231
- -1.7% vs -1.0% NCT02008682
- 4.1% vs 3.4% NCT01966978
- -1.4% vs -1.1% NCT02730377
- -1.3% vs -0.7% NCT01917656
- -1.1% vs 0.2% NCT00318422
Body weight, change (kg)
- efpeglenatide
- -1.8 vs -1.3−0.6 vs placeboNCT03353350
5 other results
- -3.2 vs -1.4 NCT03353350
- -3.2 vs -1.3 NCT03353350
- -3.3 vs -1.4 NCT03353350
- -0.9 vs -1.3 NCT03353350
- -1.0 vs -1.4 NCT03353350
- Liraglutide (Victoza)
- -2.3 vs 1.0−3.3 vs placeboNCT01541215
22 other results
- -2.5 vs -0.9 NCT01541215
- -2.9 vs 0.7 NCT00318461
- -2.8 vs 0.9 NCT00318461
- -3.0 vs 0.7 NCT00318461
- -2.6 vs 0.9 NCT00318461
- -2.1 vs 0.7 NCT00318461
- -1.8 vs 0.9 NCT00318461
- 1.2 vs 3 NCT02501161
- 2.9 vs 4.1 NCT02607306
- -1 vs 4.1 NCT02607306
- 0.2 vs 1.3 NCT03172494
- -2.5 vs 1.3 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 0.5 vs 2.2 NCT02501161
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- -3.8 vs -3.5 NCT02730377
- -3.3 vs -1.8 NCT01907854
- -4.2 vs -3.7 NCT01973231
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
HbA1c below 7%
- efpeglenatide
- —Trial running · NCT07379333
- Liraglutide (Victoza)
- 63.7% vs 36.5%+27.2 vs placeboNCT01541215
3 other results
- 51.8% vs 23.2% NCT02964247
- 76.5% vs 52.6% NCT02008682
- 44% vs 20% NCT01966978
Fasting plasma glucose, change
- efpeglenatide
- 6.5 vs 8.6−2 vs placeboNCT03353350
2 other results
- 6.8 vs 8.6 NCT03353350
- -0.9 vs 8.6 NCT03353350
- Liraglutide (Victoza)
- -1.6 vs 1.0−2.6 vs placeboNCT01541215
21 other results
- -1.1 vs 0.8 NCT01541215
- -1.2 vs -0.6 NCT00318461
- -1.7 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.6 vs -1.3 NCT00318461
- -0.8 vs -0.6 NCT00318461
- -1.1 vs -1.3 NCT00318461
- -3.9 vs -3.7 NCT02501161
- -4.1 vs -4.0 NCT02607306
- -2.6 vs -4.0 NCT02607306
- -3.6 vs -3.5 NCT03172494
- -1.9 vs -3.5 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -4.0 vs -3.8 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 6.4 vs 6.4 NCT02765399
- -2.2 vs -1.2 NCT02730377
- -2.9 vs -1.6 NCT01973231
- -2.3 vs -1.2 NCT02008682
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
3-point MACE (% with event)
- efpeglenatide
- —Trial running · NCT07379333
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. efpeglenatide: 4 of 4 rows · Liraglutide (Victoza): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | efpeglenatide | Liraglutide (Victoza) |
|---|---|---|
| Dropout rate | 21.4%6 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 2 more results23.8%4 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 19%2 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 21.1%1.8 mg dailya NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results18.3%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 3% NCT01179048 · Phase 3 15.2%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 41.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 55.2%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 6.3% NCT02765399 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 8.6% NCT01505673 · Phase 4 · registry result, not featured evidence 7.9% NCT01907854 · Phase 4 · registry result, not featured evidence 5.4% NCT01973231 · Phase 4 · registry result, not featured evidence 14.7% NCT02008682 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 16.1%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 55.1% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4% NCT03175120 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 1.5% NCT02964247 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 3.7%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 2.9%6 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 2 more results2%4 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 4%2 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 12%1.8 mg dailya NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.5%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.5%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT01179048 · Phase 3 0%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 — NCT03260881 · Phase 4 · registry result, not featured evidence 7.4% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 7.9%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence — NCT02765399 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT02014740 · Phase 4 · registry result, not featured evidence — NCT02299388 · Phase 4 · registry result, not featured evidence — NCT01505673 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01973231 · Phase 4 · registry result, not featured evidence — NCT02008682 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 8.3%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence — NCT01234649 · Phase 3 · registry result, not featured evidence · combination 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence — NCT02964247 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.2%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 6.1%6 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 2 more results5.8%4 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.8%2 mg NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 6.6%1.8 mg dailya NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results10.4%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 49.7% NCT01179048 · Phase 3 13.6%1.8 mg NCT01541215 · Phase 3 13.5%1.8 mg NCT01541215 · Phase 3 4.2%1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 38.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 9.4%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 0% NCT02765399 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 2.9% NCT01505673 · Phase 4 · registry result, not featured evidence 3% NCT01907854 · Phase 4 · registry result, not featured evidence 5.9% NCT01973231 · Phase 4 · registry result, not featured evidence 1.6% NCT02008682 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 0% NCT02889510 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 7.8%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 2.5% NCT02964247 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 5.1%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 0% NCT01937598 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 6 mg diarrhoea 25.3% (placebo 8.8%) nausea 22.2% (placebo 2%) constipation 16.2% (placebo 5.9%) NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 2 more results4 mg diarrhoea 16.5% (placebo 8.8%) nausea 14.6% (placebo 2%) constipation 13.6% (placebo 5.9%) NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2 mg nasopharyngitis 9.8% (placebo 7.8%) constipation 8.8% (placebo 5.9%) diarrhoea 8.8% (placebo 8.8%) NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 1.8 mg dailya nausea 21.5% diarrhoea 16.5% nasopharyngitis 14.9% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 32 more results1.2 mg daily nausea 17.5% nasopharyngitis 15% headache 14.2% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6 mg daily nasopharyngitis 17.8% diarrhoea 12.8% nausea 12.4% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.8 mg nausea 28.8% (placebo 13.2%) vomiting 25.8% (placebo 8.8%) diarrhoea 22.7% (placebo 16.2%) NCT01541215 · Phase 3 1.8 mg nasopharyngitis 3.8% (placebo 27.9%) vomiting 3.8% (placebo 8.8%) abdominal pain 1.9% (placebo 7.4%) NCT01541215 · Phase 3 1.8 mg hyperglycaemia 2.1% (placebo 5.9%) pharyngitis 2.1% (placebo 5.9%) abdominal pain 0% (placebo 7.4%) NCT01541215 · Phase 3 abdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 14.3%) NCT02765399 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nausea 29.1% NCT02014740 · Phase 4 · registry result, not featured evidence nausea 31.4% (placebo 19.4%) decreased in apetite 17.1% (placebo 11.1%) diarrhea 11.4% (placebo 8.3%) NCT01505673 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 16.3% decreased appetite 8.9% NCT01907854 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 12.4% lipase increased 8.4% NCT01973231 · Phase 4 · registry result, not featured evidence nausea 14.8% decreased appetite 10.9% diarrhoea 8.2% NCT02008682 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination gastrointestinal disorders 27.1% (placebo 5.7%) general disorders and administration site conditions 2.9% (placebo 0%) nervous system disorders 2.9% (placebo 2.9%) NCT02889510 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence decreased appetite 14.4% diarrhoea 14.4% lipase increased 12.2% NCT03172494 · Phase 3 · registry result, not featured evidence nausea 37.2% (placebo 2.7%) diarrhea 17.9% (placebo 17.3%) allergic reaction to liraglutide 1.3% (placebo 0%) NCT01234649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nausea 26.2% (placebo 6%) decreased appetite 9.4% (placebo 0%) diarrhoea 9.4% (placebo 3%) NCT02964247 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 34.4% constipation 13.9% diarrhoea 8.8% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence headache 12.5% (placebo 12.5%) asympomatic hyppglycaemia 6.3% (placebo 0%) nausea 6.3% (placebo 0%) NCT01937598 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 32 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
efpeglenatide
show 2 more results
Liraglutide (Victoza)
show 3 more results
show 1 more result
show 8 more results
show 7 more results
show 3 more results
show 1 more result
show 2 more results
show 8 more results
+ 126 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efpeglenatide's landscape · Liraglutide (Victoza)'s landscape